Loading...

Home
ETF
TVTX

TVTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

TVTX News

Travere Therapeutics Q4 2025 Earnings Call Highlights

Feb 20 2026seekingalpha

Travere Therapeutics Reports Q4 Profit Exceeding Expectations

Feb 19 2026Yahoo Finance

Travere Therapeutics Q4 Earnings Analysis

Feb 19 2026seekingalpha

Travere Therapeutics Reports Strong 2025 Financial Results and Growth Outlook

Feb 19 2026Yahoo Finance

Travere Therapeutics Set to Announce Q4 Earnings with Strong Estimates

Feb 18 2026seekingalpha

Travere Grants Equity Inducements to New Employees

Feb 11 2026Newsfilter

Travere Grants Inducement Equity to New Employees

Feb 11 2026Yahoo Finance

Travere Therapeutics to Present at Guggenheim Biotech Summit 2026

Feb 04 2026Newsfilter

Investigation into Potential Securities Violations at Travere Therapeutics

Jan 31 2026Globenewswire

Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics

Jan 28 2026PRnewswire

Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics

Jan 25 2026Fool

Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics

Jan 24 2026Fool

Palisades Acquires 137,768 Shares of Travere Therapeutics for $5.26 Million

Jan 24 2026NASDAQ.COM

Travere Therapeutics (TVTX) FDA Review Extended to April 13

Jan 23 2026Yahoo Finance

Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities

Jan 21 2026Benzinga

Travere Therapeutics Under Investigation as FDA Extends Drug Review Timeline

Jan 14 2026Globenewswire